EP1207906A4 - Traitement pour patients atteint d'un lymphome different de la maladie de hodgkins et qui touche la moelle osseuse, avec des anticorps anti-cd20 - Google Patents

Traitement pour patients atteint d'un lymphome different de la maladie de hodgkins et qui touche la moelle osseuse, avec des anticorps anti-cd20

Info

Publication number
EP1207906A4
EP1207906A4 EP00965561A EP00965561A EP1207906A4 EP 1207906 A4 EP1207906 A4 EP 1207906A4 EP 00965561 A EP00965561 A EP 00965561A EP 00965561 A EP00965561 A EP 00965561A EP 1207906 A4 EP1207906 A4 EP 1207906A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
patients
treatment
bone marrow
hodgkins lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00965561A
Other languages
German (de)
English (en)
Other versions
EP1207906A1 (fr
Inventor
William H Rastetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of EP1207906A1 publication Critical patent/EP1207906A1/fr
Publication of EP1207906A4 publication Critical patent/EP1207906A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00965561A 1999-08-11 2000-07-25 Traitement pour patients atteint d'un lymphome different de la maladie de hodgkins et qui touche la moelle osseuse, avec des anticorps anti-cd20 Withdrawn EP1207906A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11
US148287P 1999-08-11
PCT/US2000/040459 WO2001010462A1 (fr) 1999-08-11 2000-07-25 Traitement pour patients atteint d'un lymphome different de la maladie de hodgkins et qui touche la moelle osseuse, avec des anticorps anti-cd20

Publications (2)

Publication Number Publication Date
EP1207906A1 EP1207906A1 (fr) 2002-05-29
EP1207906A4 true EP1207906A4 (fr) 2005-07-06

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00965561A Withdrawn EP1207906A4 (fr) 1999-08-11 2000-07-25 Traitement pour patients atteint d'un lymphome different de la maladie de hodgkins et qui touche la moelle osseuse, avec des anticorps anti-cd20

Country Status (11)

Country Link
EP (1) EP1207906A4 (fr)
JP (1) JP2003513012A (fr)
CN (2) CN101259270A (fr)
AU (1) AU784971B2 (fr)
CA (1) CA2378646A1 (fr)
HK (1) HK1048945A1 (fr)
MX (1) MXPA02001398A (fr)
MY (1) MY136635A (fr)
NO (1) NO20020639L (fr)
TW (1) TWI279233B (fr)
WO (1) WO2001010462A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100358577C (zh) 1999-05-07 2008-01-02 杰南技术公司 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP3263596A1 (fr) 2002-12-16 2018-01-03 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
ZA200507805B (en) 2003-04-09 2006-12-27 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
NZ568403A (en) 2003-05-09 2009-10-30 Univ Duke CD20-specific antibodies and methods of employing same
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
EA025962B1 (ru) 2003-11-05 2017-02-28 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
EP1919505A2 (fr) 2005-07-25 2008-05-14 Trubion Pharmaceuticals, Inc. Utilisation de dose unique de molecules de liaison specifique au cd20
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
CA2654317A1 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur
CA3113365A1 (fr) 2007-07-09 2009-01-15 Genentech, Inc. Prevention de la reduction des liaisons disulfure au cours de la production recombinante de polypeptides
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
CN102264368B (zh) * 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
CA2788774A1 (fr) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Formes cristallines de 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate de sodium
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
WO2016118353A1 (fr) * 2015-01-23 2016-07-28 Immunomedics, Inc. Polythérapie avec des anticorps anti-cd74 et anti-cd20 chez des patients atteints d'un lymphome b non-hodgkinien réfractaire et récidivant
SI3303373T1 (sl) 2015-05-30 2020-07-31 Molecular Templates, Inc. Deimunizirana ogrodja A podenot Shiga toksina in celice-ciljajoče molekule, ki jih obsegajo
ES2908009T3 (es) 2015-06-24 2022-04-27 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad adaptada
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43023A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
MX2019003029A (es) * 2016-09-16 2019-09-13 Nordic Nanovector Asa Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano.
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (fr) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Therapies d'association contre les lymphomes malins a cellules b par l'administration d'anticorps anti-cd20
WO2001010460A1 (fr) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Traitement de lymphomes non hodgkiniens de grade intermediaire ou de haut grade au moyen d'un anticorps anti-cd20
EP1207904B1 (fr) * 1999-08-11 2008-03-05 Biogen Idec Inc. Nouveaux parametres cliniques de determination de la toxicite hematologique avant radioimmunotherapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (fr) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Therapies d'association contre les lymphomes malins a cellules b par l'administration d'anticorps anti-cd20
WO2001010460A1 (fr) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Traitement de lymphomes non hodgkiniens de grade intermediaire ou de haut grade au moyen d'un anticorps anti-cd20
EP1207904B1 (fr) * 1999-08-11 2008-03-05 Biogen Idec Inc. Nouveaux parametres cliniques de determination de la toxicite hematologique avant radioimmunotherapie

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 20 September 2006 (2006-09-20), LEAHY MICHAEL F. ET AL: "Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.", Database accession no. NLM16940276 *
GREGORY S.A. ET AL: "Relationship of degree of bone marrow involvement with hematologic toxicity in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I 131 tositumomab", PROC AM SOC CLIN ONC, vol. 22, 2314, Retrieved from the Internet <URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=100932> [retrieved on 20100107] *
JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 SEP 2006, vol. 24, no. 27, 20 September 2006 (2006-09-20), pages 4418 - 4425, ISSN: 1527-7755 *
NGUYEN D T ET AL: "IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients", EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 62, no. 2, February 1999 (1999-02-01), pages 76 - 82, XP001056722, ISSN: 0902-4441 *
See also references of WO0110462A1 *
TSAI D E ET AL: "Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation", BONE MARROW TRANSPLANTATION, vol. 24, no. 5, 1 September 1999 (1999-09-01), pages 521 - 526, XP002327600, ISSN: 0268-3369 *
WISEMAN ET AL: 'IDEC-Y2B8 radioimmunotherapy: Baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry' BLOOD. vol. 92, no.10, suppl. 1, part 1-2, 15 November 1998, page 417A, Abstract# 1721 *
WISEMAN G. ET AL: "RADIOIMMUNOTHERAPY: BASELINE BONE MARROW INVOLVEMENT AND PLATELET COUNT ARE BETTER PREDICTORS OF HEMATOLOGIC TOXICITY THAN DOSIMETRY", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 92, no. 10, SUPPL. 01, 15 November 1998 (1998-11-15), pages 417A, XP001056771, ISSN: 0006-4971 *
WITZIG THOMAS E ET AL: "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 12, December 1999 (1999-12-01), pages 3793 - 3803, XP002327601, ISSN: 0732-183X *

Also Published As

Publication number Publication date
NO20020639D0 (no) 2002-02-08
NO20020639L (no) 2002-04-11
CN1373671A (zh) 2002-10-09
AU784971B2 (en) 2006-08-10
EP1207906A1 (fr) 2002-05-29
TWI279233B (en) 2007-04-21
WO2001010462A1 (fr) 2001-02-15
MXPA02001398A (es) 2002-08-12
HK1048945A1 (en) 2003-04-25
CA2378646A1 (fr) 2001-02-15
CN101259270A (zh) 2008-09-10
MY136635A (en) 2008-11-28
JP2003513012A (ja) 2003-04-08
CN100389825C (zh) 2008-05-28
AU7626000A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
HK1048945A1 (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
EP1227836A4 (fr) Traitement de lymphomes non hodgkiniens de grade intermediaire ou de haut grade au moyen d&#39;un anticorps anti-cd20
AUPQ893200A0 (en) Medical residue treatment
IL133571A0 (en) Medical instrument for treating biological tissue
PT1066838E (pt) Composição para a regeneração de tecidos ósseos
IL144981A0 (en) Treatment of autoimmune disease
GB9926231D0 (en) Medical implants
PT1716853E (pt) Utiliza??o de et743 para o tratamento de cancro em seres humanos
AU138425S (en) An electrode for medical use
PL358848A1 (en) Bone treatment material
HUP0001699A2 (en) Arrangement for decanting of blood
PL340948A1 (en) Syringe, in particular that for taking blood samples from patients
EP1173470A4 (fr) Traitement de troubles osseux a base d&#39;adrenomedulline ou d&#39;agonistes de l&#39;adrenomedulline
AU5215300A (en) Dental treatment area
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
IL143990A0 (en) Bone stimulating factor
EP1202751A4 (fr) Sterilisateur medical
GB9904252D0 (en) Composition for the treatment of pain
GB2341099B (en) Clinical table for treatment of the spine
GB0130539D0 (en) Bone marrow-specific protein
AUPQ421299A0 (en) Treatment of bone disorder
GB2341314B (en) Medical patient suspension apparatus
GB9903558D0 (en) Medical treatment
AU140446S (en) Tissue processing instrument
GB9912076D0 (en) Appliance for medical treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020308

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20050523

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100729

18W Application withdrawn

Effective date: 20100729